A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA - Regional Cancer Care Associates LLC

Clinical Trials

A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND KPT-8602 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Type of Cancer

Warning: implode(): Invalid arguments passed in /home/region33/public_html/wp-content/themes/regionalcancercenter/single-clinical-trials.php on line 42
Locations
Sponsor
Karyopharm
Protocol Number
Karyppharm KCP-8602-801
Cancer Diagnosis
To Learn More Call
201-510-0910